CLRO News & Events

ClearOne trading halted, volatility trading pause

Vivani Medical (VANI) announced that it has entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, ClearOne (CLRO) and a wholly owned subsidiary of ClearOne, pursuant to which Cortigent will become a wholly owned subsidiary of ClearOne upon consummation. In connection with the transaction, ClearOne has agreed to file a registration statement on Form S-1 to raise a minimum of $10M and a maximum of $15M concurrently with the closing of the transaction. As consideration for all of the issued and outstanding shares of common stock of Cortigent, Vivani will receive 12,500,000 shares of common stock of ClearOne. It is anticipated that Vivani will own 59.4% to 67.5% of the outstanding equity in the combined company and the former shareholders of ClearOne will own 12.7% to 14.4% of the outstanding equity in the combined company. ClearOne will be renamed Cortigent Holdings and is expected to trade under Nasdaq ticker symbol (CRGT). Upon closing, the combined company will be majority-owned by Vivani and will operate independently under the oversight of the reconstituted board of directors. The transaction has been unanimously approved by the boards of directors of both Vivani and ClearOne and is expected to close in the third quarter of 2026, subject to customary closing conditions, including receipt of the required stockholder approvals, closing of the financing, meeting the minimum net cash requirements set forth in the agreement, and the continued listing of the combined company's common stock on Nasdaq.

ClearOne (CLRO) entered into a definitive agreement and plan of merger among its wholly-owned subsidiary, Vivani Medical (VANI), and Cortigent, a wholly-owned subsidiary of Vivani, pursuant to which Cortigent will become a wholly-owned subsidiary of ClearOne upon consummation. In connection with the Transaction, ClearOne has agreed to file a registration statement on Form S-1 to raise a minimum of $10,000,000 and a maximum of $15,000,000 concurrently with the closing of the Transaction. As consideration for all of the issued and outstanding shares of common stock of Cortigent, Vivani will receive 12,500,000 shares of common stock in the capital of ClearOne. It is anticipated that Vivani will own 59.4% to 67.5% of the outstanding equity in the combined company and the former shareholders of ClearOne will own 12.7% to 14.4% of the outstanding equity in the Combined Company. ClearOne will be renamed "Cortigent Holdings, Inc" and is expected to trade under Nasdaq ticker symbol "CRGT." Upon Closing, the Combined Company will be majority-owned by Vivani and will operate independently under the oversight of the reconstituted board of directors. The Transaction has been unanimously approved by the boards of directors of both Vivani and ClearOne and is expected to close in the third quarter of 2026, subject to customary closing conditions, including receipt of the required stockholder approvals, closing of the Financing, meeting the minimum net cash requirements set forth in the Agreement, and the continued listing of the Combined Company's common stock on Nasdaq.